Strs Ohio Grows Stock Holdings in Labcorp Holdings Inc. $LH

Strs Ohio increased its stake in shares of Labcorp Holdings Inc. (NYSE:LH) by 4.9% during the fourth quarter, Holdings Channel reports. The institutional investor owned 86,002 shares of the medical research company’s stock after acquiring an additional 4,004 shares during the period. Strs Ohio’s holdings in Labcorp were worth $21,576,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. JPL Wealth Management LLC purchased a new stake in Labcorp during the third quarter worth about $28,000. Thurston Springer Miller Herd & Titak Inc. purchased a new stake in Labcorp during the fourth quarter worth about $26,000. Motco purchased a new stake in Labcorp during the third quarter worth about $32,000. Eagle Bay Advisors LLC purchased a new stake in Labcorp during the fourth quarter worth about $29,000. Finally, Hantz Financial Services Inc. boosted its holdings in Labcorp by 48.8% during the third quarter. Hantz Financial Services Inc. now owns 122 shares of the medical research company’s stock worth $35,000 after buying an additional 40 shares in the last quarter. Hedge funds and other institutional investors own 95.94% of the company’s stock.

Labcorp Stock Performance

Shares of LH opened at $256.37 on Monday. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.54 and a current ratio of 1.73. The company has a market capitalization of $21.07 billion, a price-to-earnings ratio of 22.71, a PEG ratio of 1.72 and a beta of 0.91. The company’s 50 day simple moving average is $270.69 and its 200 day simple moving average is $267.33. Labcorp Holdings Inc. has a 1 year low of $239.67 and a 1 year high of $293.72.

Labcorp (NYSE:LH) last announced its quarterly earnings data on Thursday, April 30th. The medical research company reported $4.25 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.09 by $0.16. The business had revenue of $3.54 billion for the quarter, compared to the consensus estimate of $3.51 billion. Labcorp had a net margin of 6.66% and a return on equity of 16.29%. The company’s quarterly revenue was up 5.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $3.84 earnings per share. Labcorp has set its FY 2026 guidance at 17.700-18.350 EPS. On average, sell-side analysts predict that Labcorp Holdings Inc. will post 18 EPS for the current year.

Labcorp Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, June 11th. Investors of record on Friday, May 29th will be paid a dividend of $0.72 per share. The ex-dividend date of this dividend is Friday, May 29th. This represents a $2.88 annualized dividend and a dividend yield of 1.1%. Labcorp’s dividend payout ratio is presently 27.53%.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the stock. JPMorgan Chase & Co. boosted their price objective on shares of Labcorp from $319.00 to $330.00 and gave the stock an “overweight” rating in a report on Wednesday, February 18th. Morgan Stanley reaffirmed an “overweight” rating on shares of Labcorp in a report on Tuesday, February 17th. Wall Street Zen raised shares of Labcorp from a “hold” rating to a “buy” rating in a report on Saturday. Weiss Ratings raised shares of Labcorp from a “hold (c+)” rating to a “buy (b-)” rating in a report on Tuesday, February 10th. Finally, Piper Sandler upped their price target on shares of Labcorp from $270.00 to $300.00 and gave the company a “neutral” rating in a report on Tuesday, February 24th. Eight research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $308.00.

Trending Headlines about Labcorp

Here are the key news stories impacting Labcorp this week:

• Positive Sentiment: Q1 results beat Street estimates — EPS of $4.25 vs. $4.09 est. and revenue of $3.54B vs. $3.51B, with revenue up ~5.8% year‑over‑year. Management pointed to broad segment growth driving the beat. Labcorp Announces 2026 First Quarter Results; Raises Full Year 2026 Guidance
• Positive Sentiment: Raised FY2026 guidance — EPS guidance range set to $17.70–$18.35 and revenue guidance roughly $14.7B–$14.8B, reflecting steady diagnostics demand that management says supports continued growth. Labcorp raises full-year forecasts on steady diagnostics demand
• Positive Sentiment: Analyst reaction was initially favorable — outlets noted pre‑market gains after the beat and the raised view, signaling positive near‑term sentiment from some desks. LH Stock Up in Pre-Market on Q1 Earnings & Revenue Beat, 2026 View Up
• Neutral Sentiment: Full earnings materials and call transcript are available for deeper review (slides, PR, and call transcript). Useful for investors who want line‑by‑line detail on margins, segment trends and cadence. Labcorp Holdings Inc. 2026 Q1 – Results – Earnings Call Presentation Labcorp Holdings Inc. (LH) Q1 2026 Earnings Call Transcript
• Neutral Sentiment: Longer‑term valuation context: coverage pieces highlight LH as a value/quality name given its margin profile and ROE, which may attract income/value investors. Here’s Why Labcorp Holdings (LH) is a Strong Value Stock
• Negative Sentiment: Market reaction turned muted/negative intraday — reasons include guidance that is only modestly above consensus (company range roughly in line with Street forecasts), possible profit‑taking after the beat, and limited incremental upside in margin guidance. This helps explain why the stock is down despite the beat. Compared to Estimates, Labcorp (LH) Q1 Earnings: A Look at Key Metrics

Insider Activity

In related news, EVP Brian J. Caveney sold 1,500 shares of the company’s stock in a transaction that occurred on Tuesday, February 24th. The shares were sold at an average price of $286.31, for a total transaction of $429,465.00. Following the transaction, the executive vice president owned 30,107 shares of the company’s stock, valued at approximately $8,619,935.17. This represents a 4.75% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Jonathan C. Meltzer sold 87 shares of the company’s stock in a transaction that occurred on Thursday, February 12th. The shares were sold at an average price of $290.42, for a total transaction of $25,266.54. Following the transaction, the executive vice president directly owned 2,782 shares in the company, valued at $807,948.44. The trade was a 3.03% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 16,113 shares of company stock worth $4,547,450. 0.84% of the stock is currently owned by corporate insiders.

Labcorp Company Profile

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.